Avinger, Inc.

  • Market Cap: Micro Cap
  • Industry: Medical Specialties
  • ISIN: US0537348775
USD
0.47
-0.12 (-20.74%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Avinger, Inc. stock-summary
stock-summary
Avinger, Inc.
Medical Specialties
Avinger, Inc., (Avinger) is a commercial-stage medical device company. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with the peripheral arterial disease (PAD). The Company manufactures and sells a suite of products in the United States and select international markets. Avinger’s products include its Lightbox imaging console, the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (CTO), and Pantheris, an image-guided atherectomy device which is designed to allow physicians to precisely remove arterial plaque in PAD patients. The lumivascular platform offers real-time visualization of the inside of the artery during PAD treatment. The lumivascular platform consists of a capital component Lightbox and a range of disposable catheter products, including Ocelot, Ocelot PIXL, Ocelot MVRX and Pantheris.
Company Coordinates stock-summary
Company Details
400 Chesapeake Dr , REDWOOD CITY CA : 94063-4739
stock-summary
Tel: 1 650 36324001 214 5978200
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 2 Schemes (1.6%)

Foreign Institutions

Held by 3 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. James Cullen
Non-Executive Independent Chairman of the Board
Mr. Jeffrey Soinski
President, Chief Executive Officer, Director
DR. Tamara Elias
Independent Director
Mr. James McElwee
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
2 Million
(Quarterly Results - Sep 2024)
Net Profit:
-4 Million
stock-summary
Industry

Medical Specialties

stock-summary
Market cap

USD 2 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.13

stock-summary
Return on Equity

-480.23%

stock-summary
Price to Book

0.40